Healthcare policy expert Indu Bhushan. File

Healthcare policy expert Indu Bhushan. File | Photo Credit: The Hindu

Healthcare policy expert and former CEO of the National Health Authority Indu Bhushan, in an exclusive interview with The Hindu, examined whether the National Pharmaceutical Pricing Authority’s (NPPA) recent decision to cap trade margins on 137 anti-cancer medicines will translate into meaningful savings for patients.

Drawing on his experience implementing the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), he highlights the need for pricing transparency, regulatory oversight and sustainable healthcare financing.

Published - October 29, 2026 06:57 pm IST

Source: The Hindu · Bindu Shajan Perappadan

At a glance

Topic
Health
Country
🇮🇳 IN
Publisher language
EN
Added to Allnira